HIGH IMPACT – Neurocrine announced that the FDA accepted its IND for NBI-1117568 (selective M4 agonist). The company says that it anticipates initiating a Phase 2 study evaluating NBI-1117568 in Schizophrenia in H2 2022.
Neurocrine is developing NBI-1117568 in partnership with Sosei Heptares under a multi-program muscarinic receptor agonist collaboration agreement established between the two companies in late 2021.
Although Karuna’s M1/M4 muscarinic agonist, KarTx, will be the first to market, NBI-1117568 will likely present a stronger competitive threat to Emraclidine.
NBI-1117568 will be a key program for Cerevel to track and differentiate itself from as clinical development progresses.